ArticleAfrican health sciences2024
The predictive prognostic value of serum CEA, CA153, HE4 combined with a variety of immune inflammatory indicators in breast cancer.
Article in African health sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Development and validation of an interpretable model based on ultrasound radiomics for predicting Ki-67 expression levels in breast cancer.Translational cancer research · 2026Article
- A circulating microRNA-based diagnostic model for breast cancer, in which the miR-139-3p/RPA2 axis regulates the sensitivity to DNA-damaging agents.Translational cancer research · 2026Article
- Editor's choice: Infections, sexual reproductive health and non-communicable diseases.African health sciences · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To investigate the prognostic value of serum carcinoembryonic antigen (CEA), carbohydrate antigen (CA153), and human epididymal 4 (HE4) combined with a variety of immune inflammatory indicators in breast cancer. Methods: A sample size of 112 breast cancer patients was selected and all patients underwent surgical treatment. The three-year prognosis of the patients was observed. Patients with poor prognoses were included in the poor prognoses group and the patients with good prognosis were included in the good prognosis group. The levels of serum CEA, CA153, HE4, and related immune inflammatory indicators (including Mon, Lym, Neu, Plt, NLR, and SII) were analysed. The predictive value of serum CEA, CA153, HE4, and immune inflammatory indicators on the prognosis of breast cancer was analysed by Logistic regression and ROC curve method. The area under the ROC curve (AUC) was used to evaluate the predictive efficiency. α=0.05 was used as the test standard. Results: Compared with the good prognosis group, the CEA, CA153, HE4, Mon, Neu, Plt, and SII of the poor prognosis group were higher, all P<0.05. Logistic regression analysis showed that CEA, CA153, HE4, Neu, and Plt were effective indicators for predicting the poor prognosis of breast cancer. The AUC of CEA, CA153, HE4, Neu, and Plt in predicting the prognosis of breast cancer was 0.929, which was higher than the AUC of a single prediction. Conclusion: Serum CEA, CA153, HE4 combined with Neu and Plt had predictive value for the prognosis of breast cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.